Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs

Gao, Jingjing; Xia, Ziting; Mary, Helna B.; Joseph, John; Luo, James; Joshi, Nitin

doi:10.1016/j.tips.2021.12.004

Cited by 37 publications

(24 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S1 ). This particle size is appropriate since the microgels will not be susceptible to rapid clearance via lymphatics and microvasculature [ 59 ]. Once transferred to a physiological calcium concentration, the microparticle size (150.8 ± 1.1 μm) was similar to the mold's original size, demonstrating the excellent size tunability and fidelity of the micromolding technique.…”

Section: Discussionmentioning

confidence: 99%

Micromolding-based encapsulation of mesenchymal stromal cells in alginate for intraarticular injection in osteoarthritis

Nativel¹,

Smith²,

Boulestreau³

et al. 2023

Materials Today Bio

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Micromolding-based encapsulation of mesenchymal stromal cells in alginate for intraarticular injection in osteoarthritis

Nativel¹,

Smith²,

Boulestreau³

et al. 2023

Materials Today Bio

View full text Add to dashboard Cite

“…For example, vascular physiology varies between patients, which can greatly influence the distribution and delivery of systemically administered nanoparticles . Similarly, the mechanical loading in knee joints can impact an intra-articular drug delivery system, but it varies between patients with early or late-stage osteoarthritis due to differences in their level of physical activity . Design criteria for developing future drug delivery systems should consider such heterogeneities.…”

Section: Building Personalized Therapiesmentioning

confidence: 99%

“…32 Similarly, the mechanical loading in knee joints can impact an intraarticular drug delivery system, but it varies between patients with early or late-stage osteoarthritis due to differences in their level of physical activity. 33 Design criteria for developing future drug delivery systems should consider such heterogeneities. Ultimately, modular drug delivery systems that match specific therapies to patient subtypes are needed.…”

Section: ■ Building Personalized Therapiesmentioning

confidence: 99%

The Future of Drug Delivery

et al. 2023

Self Cite

View full text Add to dashboard Cite

NotesViews expressed in this editorial are those of the authors and not necessarily the views of the ACS. J.M.K. is a paid consultant and or equity holder for multiple biotechnology companies (see https://www.karplab.net/team/ jeff-karp) and holds multiple patents on drug delivery. The interests of J.M.K. were reviewed and are subject to a management plan overseen by his institutions in accordance with its conflict of interest policies. N.J. holds multiple patents on drug delivery and is an equity holder and a paid consultant for a biotech company (Akita Biosciences). R.L. is a paid consultant and or equity holder for multiple biotechnology companies (see www.dropbox.com/s/yc3xqb5s8s94v7x/ Rev%20Langer%20COI.pdf?dl=0) and holds multiple patents on drug delivery. ■ ACKNOWLEDGMENTSThe authors appreciate the assistance from Ziting (Judy) Xia in drawing the figure. The figure was created with BioRender.

show abstract

“…The pathological changes of OA mainly include wear and tear degeneration of articular cartilage, formation of bone fragments, synovial inflammation and subchondral bone remodeling [4]. As the specific pathogenesis of OA is still unknown, the current clinical treatment of OA is mainly focused on relieving joint pain and delaying the development of OA [5][6][7]. Currently, drug therapy, physical therapy and surgery are the primary treatments [8,9].…”

Section: Introductionmentioning

confidence: 99%

Targeted and responsive biomaterials in osteoarthritis

Li¹,

Zhang²,

Han³

et al. 2023

Theranostics

View full text Add to dashboard Cite

Osteoarthritis (OA) is a degenerative disease characterized by loss of articular cartilage and chronic inflammation, involving multiple cellular dysfunctions and tissue lesions. The non-vascular environment and dense cartilage matrix in the joints tend to block drug penetration, resulting in low drug bioavailability. There is a desire to develop safer and more effective OA therapies to meet the challenges of an aging world population in the future. Biomaterials have achieved satisfactory results in improving drug targeting, prolonging the duration of action, and achieving precision therapy. This article reviews the current basic understanding of the pathological mechanisms and clinical treatment dilemmas of OA, summarizes and discusses the advances for different kinds of targeted and responsive biomaterials in OA, seeking to provide new perspectives for the treatment of OA. Subsequently, limitations and challenges in clinical translation and biosafety are analyzed to guide the development of future therapeutic strategies for OA. As the need for precision medicine rises over time, emerging multifunctional biomaterials based on tissue targeting and controlled release will become an irreplaceable part of OA management.

show abstract

Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs

Cited by 37 publications

References 95 publications

Micromolding-based encapsulation of mesenchymal stromal cells in alginate for intraarticular injection in osteoarthritis

Micromolding-based encapsulation of mesenchymal stromal cells in alginate for intraarticular injection in osteoarthritis

The Future of Drug Delivery

Targeted and responsive biomaterials in osteoarthritis

Contact Info

Product

Resources

About